Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACHV

ACHV - Achieve Life Sciences Inc Stock Price, Fair Value and News

3.82USD-0.18 (-4.50%)Market Closed
Watchlist

Market Summary

USD3.82-0.18
Market Closed
-4.50%

ACHV Stock Price

View Fullscreen

ACHV RSI Chart

ACHV Valuation

Market Cap

80.9M

Price/Earnings (Trailing)

-2.27

Price/Sales (Trailing)

18.98

EV/EBITDA

-6.82

Price/Free Cashflow

-3.07

ACHV Price/Sales (Trailing)

ACHV Profitability

EBT Margin

-323.88%

Return on Equity

-880.91%

Return on Assets

-146.16%

Free Cashflow Yield

-32.53%

ACHV Fundamentals

ACHV Revenue

Revenue (TTM)

5.1M

ACHV Earnings

Earnings (TTM)

-35.6M

Earnings Growth (Yr)

45.65%

Earnings Growth (Qtr)

13.73%

Breaking Down ACHV Revenue

Last 7 days

-4%

Last 30 days

0.7%

Last 90 days

-18.5%

Trailing 12 Months

-19.4%

How does ACHV drawdown profile look like?

ACHV Financial Health

Current Ratio

5.36

Debt/Equity

4.01

Debt/Cashflow

-1.93

ACHV Investor Care

Shares Dilution (1Y)

117.96%

Diluted EPS (TTM)

-2.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
201619.7M17.8M11.1M5.1M
201516.8M15.9M17.8M18.2M
201436.5M35.1M30.1M27.1M
201323.9M27.8M31.1M29.9M
20125.6M6.2M11.6M20.1M
201110.1M10.3M6.6M5.5M
201022.6M19.6M16.6M13.6M
200900025.5M

Tracking the Latest Insider Buys and Sells of Achieve Life Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 30, 2023
bencich john
bought
27,500
5.5
5,000
ceo
Apr 28, 2023
jacobs cindy
acquired
-
-
2,500
president & cmo
Apr 28, 2023
wan jerry
acquired
-
-
1,250
principal accounting officer
Apr 28, 2023
wan jerry
sold (taxes)
-5,546
8.29
-669
principal accounting officer
Apr 28, 2023
bencich john
sold (taxes)
-15,145
8.29
-1,827
ceo
Apr 28, 2023
stewart richard alistair
acquired
-
-
5,000
executive chairman
Apr 28, 2023
jacobs cindy
sold (taxes)
-5,048
8.29
-609
president & cmo
Apr 28, 2023
bencich john
acquired
-
-
7,500
ceo
Apr 28, 2023
stewart richard alistair
sold (taxes)
-18,652
8.29
-2,250
executive chairman
Apr 21, 2023
wan jerry
sold (taxes)
-20,468
6.8
-3,010
principal accounting officer

1–10 of 50

Which funds bought or sold ACHV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
AWM Investment Company, Inc.
sold off
-100
-1,171,750
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
sold off
-100
-29,184
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
1.98
-58,473
2,495,520
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-101,502
-
-%
Feb 14, 2024
PRELUDE CAPITAL MANAGEMENT, LLC
sold off
-100
-109,345
-
-%
Feb 14, 2024
LPL Financial LLC
added
8.51
28,070
735,420
-%
Feb 14, 2024
J. Goldman & Co LP
new
-
278,104
278,104
0.01%
Feb 14, 2024
STATE STREET CORP
unchanged
-
-11,397
260,862
-%
Feb 14, 2024
Long Focus Capital Management, LLC
unchanged
-
-44,658
1,022,170
0.03%

1–10 of 41

Are Funds Buying or Selling ACHV?

Are funds buying ACHV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACHV
No. of Funds

Unveiling Achieve Life Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 02, 2023
contrarian alpha, lp
9.2%
1,978,377
SC 13G/A
Apr 18, 2023
dialectic capital management, lp
19.68%
3,538,093
SC 13G
Mar 23, 2023
dialectic capital management, lp
19.5%
3,494,000
SC 13D/A
Mar 06, 2023
dialectic capital management, lp
19.5%
3,494,000
SC 13D/A
Feb 13, 2023
francis capital management, llc
3.6%
648,648
SC 13G/A
Feb 10, 2023
svb financial group
8.8%
1,716,764
SC 13G/A
Jan 20, 2023
dialectic capital management, lp
19.5%
3,494,000
SC 13D
Nov 28, 2022
contrarian achieve spv, lp
369%
1,318,918
SC 13G
Nov 22, 2022
svb financial group
8.7%
1,706,805
SC 13G/A
Nov 21, 2022
dialectic capital management, lp
19.5%
3,494,000
SC 13G

Recent SEC filings of Achieve Life Sciences Inc

View All Filings
Date Filed Form Type Document
Jan 29, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Dec 11, 2023
8-K
Current Report

Peers (Alternatives to Achieve Life Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Achieve Life Sciences Inc News

Latest updates
MarketBeat20 Feb 202408:48 am
Yahoo Finance2 months ago

Achieve Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2016Q42016Q32016Q22016Q12015Q42015Q32015Q22015Q12014Q42014Q32014Q22014Q12013Q42013Q32013Q22013Q12012Q42012Q32012Q22012Q12011Q4
Revenue---2,122,0002,940,0006,024,0006,737,0004,025,0001,374,0005,653,0004,803,0004,929,00011,731,0008,604,0009,862,0006,340,0005,076,0009,780,0006,570,0002,429,0001,316,0001,236,000
Operating Expenses----7,372,0009,503,00011,428,000-6,371,00012,318,00012,045,000-----------
Earnings Before Taxes-51.4%-613,000-405,000-------------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-15.8%24.0029.0021.0030.0024.0034.0041.0048.0038.0046.0034.0040.0028.0016.0017.0021.0011.0015.0015.0019.0017.00
  Current Assets-17.0%22.0026.0018.0027.0021.0031.0038.0045.0035.0042.0030.0037.0024.0013.0013.0017.008.0011.0011.0016.0014.00
    Cash Equivalents-20.7%20.0025.0017.0025.0018.0029.0036.0043.0033.0042.0030.0036.0022.0012.0012.0017.007.0010.007.0010.0012.00
  Net PPE---------0.000.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill0%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities5.6%20.0019.0020.0022.0023.0021.0019.0019.003.005.004.003.002.002.002.003.003.003.004.003.003.00
  Current Liabilities18.4%4.003.0020.0022.007.005.004.005.003.005.004.003.002.002.002.003.003.003.004.003.003.00
  Long Term Debt2.9%16.0016.00--16.0015.0015.0015.00-------------
    LT Debt, Current---16.0016.00-----------------
    LT Debt, Non Current2.9%16.0016.00--16.0015.0015.0015.00-------------
Shareholder's Equity-58.4%4.0010.000.008.001.0013.0021.0028.0035.0041.0030.0037.0026.0015.0015.0018.008.0012.0010.0016.0014.00
  Retained Earnings-4.6%-160-153-144-135-124-111-101-93.59-86.43-79.70-68.43-60.43-55.71-51.95-49.02-45.70-42.51-38.84-31.29-25.38-21.74
  Additional Paid-In Capital0.9%16416314514412612512312212112198.0098.0081.0066.0064.0064.0051.0050.0041.0041.0036.00
Shares Outstanding0.3%21.0021.0018.0018.0010.0010.009.009.008.007.006.003.00---------
Float------47.00---85.00---15.00---15.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations23.1%-5,136-6,679-8,300-11,123-11,307-8,340-6,779-5,218-8,694-9,076-6,452-2,480-4,335-2,198-4,461-3,414-3,072-3,841-4,889-3,541-2,981
  Share Based Compensation-1.3%1,1741,1891,085778829840823494530621542395281308302284310317290266210
Cashflow From Investing--------------3.00-12.00-2.00-1.00-2,3472,690-3,709-1,390
Cashflow From Financing-100.0%-15,23147.0017,6931261,38195.0014,9288.0021,43823615,94014,6202,167-47.0012,703---5,010846

ACHV Income Statement

2023-09-30
Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
EXPENSES    
Research and development$ 3,581$ 9,869$ 13,700$ 21,464
General and administrative2,9912,7709,1648,474
Total operating expenses6,57212,63922,86429,938
OTHER INCOME (EXPENSE)    
Interest income2627361781
Interest expense [note 7](781)(481)(2,066)(1,242)
Other expense(17)(30)(26)(19)
Total other expense(536)(438)(1,475)(1,180)
Net loss and comprehensive loss$ (7,108)$ (13,077)$ (24,339)$ (31,118)
Basic net loss per common share [note 8[d]]$ (0.34)$ (1.35)$ (1.26)$ (3.24)
Diluted net loss per common share [note 8[d]]$ (0.34)$ (1.35)$ (1.26)$ (3.24)
Weighted average shares used in computation of basic net loss per common share [note 8[d]]21,127,2819,693,78819,376,3169,600,947
Weighted average shares used in computation of diluted net loss per common share [note 8[d]]21,127,2819,693,78819,376,3169,600,947

ACHV Balance Sheet

2023-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents [note 6]$ 19,919$ 24,771
Grant receivable [note 3]83105
Prepaid expenses and other assets1,8952,454
Total current assets21,89727,330
Right-of-use assets [note 9]8066
Other assets and restricted cash [note 6]74123
License agreement [note 4 and note 5]1,2521,418
Goodwill [note 5]1,0341,034
Total assets24,33729,971
Current liabilities:  
Accounts payable6381,660
Accrued liabilities other693403
Accrued clinical liabilities9901,729
Accrued compensation1,7001,678
Current portion of long-term obligations [note 9]6158
Convertible debt [note 6 and note 7] 16,071
Total current liabilities4,08221,599
Convertible debt [note 7]16,195 
Long-term obligations [note 9]2269
Total liabilities20,29921,668
Commitments and contingencies [note 9]
Stockholders' equity:  
Common stock, $0.001 par value, 150,000,000 shares authorized, 21,165,760 issued and outstanding at September 30, 2023 and 17,897,029 issued and outstanding at December 31, 20229087
Additional paid-in capital164,219144,148
Accumulated deficit(160,275)(135,936)
Accumulated other comprehensive income44
Total stockholders' equity4,0388,303
Total liabilities and stockholders' equity24,33729,971
Series A Convertible Preferred Stock [Member]  
Stockholders' equity:  
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]  
Stockholders' equity:  
Convertible preferred stock, value
ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.
 CEO
 WEBSITEwww.achievelifesciences.com
 EMPLOYEES20

Achieve Life Sciences Inc Frequently Asked Questions


What is the ticker symbol for Achieve Life Sciences Inc? What does ACHV stand for in stocks?

ACHV is the stock ticker symbol of Achieve Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Achieve Life Sciences Inc (ACHV)?

As of Thu Feb 22 2024, market cap of Achieve Life Sciences Inc is 80.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACHV stock?

You can check ACHV's fair value in chart for subscribers.

What is the fair value of ACHV stock?

You can check ACHV's fair value in chart for subscribers. The fair value of Achieve Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Achieve Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACHV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Achieve Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ACHV is over valued or under valued. Whether Achieve Life Sciences Inc is cheap or expensive depends on the assumptions which impact Achieve Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACHV.

What is Achieve Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ACHV's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 18.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACHV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Achieve Life Sciences Inc's stock?

In the past 10 years, Achieve Life Sciences Inc has provided -0.58 (multiply by 100 for percentage) rate of return.